Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 23Completed 12Terminated 2Recruiting 2Enrolling by invitation 2Not yet recruiting 1

Sponsor Class

OTHER 237INDUSTRY 104NIH 48NETWORK 20OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 15Breast 8Lymphoid 7Genitourinary 6Thoracic 5Other hematologic neoplasm 4Head & Neck 4Sarcoma 2Plasma cell 2Other solid neoplasm 1Other 1Myeloid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Sarcoma, Kaposi 2HIV Infections 1Castleman Disease 1

Interventions

Rituximab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER_GOV × Sarcoma × Clear all
NCT01412515 2026-06-04

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

Institut National de la Santé Et de la Recherche Médicale, France

Phase 2 Terminated
11 enrolled
Sarcoma

Sarcoma, Kaposi

NCT00127569 2007-01-12

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

French National Agency for Research on AIDS and Viral Hepatitis

Phase 2 Terminated
25 enrolled
LymphoidSarcoma

Castleman Disease, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡